Almirall Focus Firmly On Lebrikizumab After Securing Klisyri Approval

Big Quarter Ahead For Spanish Group

Now that the actinic keratosis treatment Klisyri has got the green light in Europe, the Spanish firm's attention will be on atopic dermatitis and forthcoming Phase III data on lebrikizumab, a potential rival to Dupixent.

Almirall headquarters
Big quarter coming up for the Barcelona-based firm • Source: Archive

With eagerly anticipated Phase III data imminent on the atopic dermatitis drug lebrikizumab, Almirall SA has got off to a good start for what will be a pivotal third quarter by obtaining EU approval for its actinic keratosis (AK) therapy Klisyri.

Two months after receiving a positive opinion from the Committee for Medicinal Products for Human Use (CHMP), the European Commission...

Scrip Podcast

Keep up with the top pharma business news of the week. On the go.

Scrip brings you a weekly bulletin of top picks.

More from New Products

More from Scrip